Stockscreener 앱 받기
0.85
2.30%
-0.02
시간 외 거래:
.89
0.04
+4.71%
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
LEXX: GLP-1-H25-5 Study Complete - Yahoo Finance
Lexaria Bioscience announces completion of GLP-1-H25-5 study - Yahoo Finance
Lexaria’s Oral Liraglutide Shows Promise in Reducing Adverse Events - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results for Oral Liraglutide Study | LEXX Stock News - GuruFocus
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule | LEXX Stock News - GuruFocus
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule - TradingView
GLP-1 Breakthrough: Oral Liraglutide Shows 67% Less Nausea in Clinical Trial | LEXX Stock News - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Trading Up 4.3% – Still a Buy? - Defense World
Lexaria Bioscience to Engage with Industry Leaders at BIO International Convention - TipRanks
Lexaria Attending BIO International Convention | LEXX Stock News - GuruFocus
Lexaria Attending BIO International Convention - TradingView
Lexaria Targets Weight Loss and Diabetes Partnerships at Massive BIO Convention with 20,000 Attendees - Stock Titan
Lexaria Bioscience stock hits 52-week low at $0.94 By Investing.com - Investing.com South Africa
Lexaria Bioscience stock hits 52-week low at $0.94 - Investing.com
Lexaria Bioscience Corp (NASDAQ: LEXX) Is Down -15.79% Since Its Low, And It’s Only Getting Started. - Stocksregister
Lexaria advances drug delivery tech with PharmaCO By Investing.com - Investing.com Nigeria
Raymond James Financial Inc. Makes New Investment in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria (LEXX) Advances Collaborative Pharmaceutical Research | - GuruFocus
Lexaria Advances Collaboration with Pharma Partner on Drug Delivery Technology - TipRanks
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - marketscreener.com
Lexaria Provides Update on Material Transfer Agreement with Phar - GuruFocus
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Bioscience stock hits 52-week low at $1.14 By Investing.com - Investing.com India
Lexaria Bioscience stock hits 52-week low at $1.14 - Investing.com Australia
Lexaria Announces Closing of $2 Million Registered Direct Offeri - GuruFocus
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock - Yahoo Finance
Lexaria Bioscience Secures $2 Million in Direct Stock Offering - TipRanks
Lexaria Secures $2M Strategic Investment in Clean Direct Offering Amid Market Turbulence - Stock Titan
Market Watch Highlights: Lexaria Bioscience Corp (LEXX) Ends on an Downturn Note at 1.35 - DWinneX
Lexaria Bioscience Corp (LEXX) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
What is Zacks Small Cap’s Estimate for LEXX FY2025 Earnings? - Defense World
Lexaria Bioscience (LEXX) Announces $2M Direct Offering | LEXX S - GuruFocus
Lexaria Bioscience Secures $2 Million in Registered Direct Stock Offering - citybuzz -
Lexaria Announces $2 Million Registered Direct Offering of Commo - GuruFocus
Lexaria Bioscience secures $2 million in direct offering By Investing.com - Investing.com South Africa
Lexaria Bioscience secures $2 million in direct offering - Investing.com
Lexaria Announces $2 Million Registered Direct Offering of Common Stock - TradingView
Lexaria Lands $2M Strategic Investment: Institutional Investor Backs Biotech at $1.00 Per Share - Stock Titan
Lexaria Bioscience (OTCMKTS:LXRP) versus U.S. Gold (NASDAQ:USAU) Critical Comparison - Defense World
LEXXLexaria Bioscience Corp Latest Stock News & Market Updates - Stock Titan
LEXX: Second Quarter Results - Yahoo Finance
Lexaria Bioscience (LEXX) Advances in GLP-1 Technology Amid Indu - GuruFocus
0.39%
0.42%
자본화:
|
볼륨(24시간):